Stand aside — setup invalidated
Setup score 55, but price closes below stop $234.36 — stand aside until the condition resets.
Simple research view
MRNA · Moderna, Inc.
$198.85 -0.62% Oct 26 close
1 independent risk warning also present. Review before relying on the bullish setup.
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$MRNA
Moderna, Inc.Moderna, Inc. is a large-cap Biotechnology company in the Health Technology sector with a market cap of $79B.
⚠ Risk Signals
Bearish RSI Divergence
Price higher high ($174.38→$203.46) but RSI lower high (92→76) — momentum diverging
Bearish structure on the daily chart — a heads-up for anyone holding, not a short signal. Does not affect the bullish setup score.
Market Structure
Trend structure: uptrend
Latest event: bos
(bullish)
Support
45.40–45.62
· 3 touches · moderate
Support
59.48–59.55
· 3 touches · moderate
Verdict · setup score 55/100 · data Oct 26 close · latest session
Stand aside — setup invalidated
Setup score 55, but price closes below stop $234.36 — stand aside until the condition resets.
Recent price action · daily
What would change this verdict
What needs to turn for this to become buyable — the top failing checks across the legend council:
- Minervini 2. ROE ≥ 17% — ROE -39.2%
- Minervini 2. Revenue growth ≥ 20% YoY — -39.9% YoY
- O'Neil A: Annual earnings & revenue quality — Rev -39.9% | ROE -39.2%
- O'Neil N: Near 52-week high or RS line new high — 21.9% below high | RS line new high: False
- Weinstein Volume expansion above average — Volume ratio 0.68x
- Dennis S1: 20-day Donchian breakout
Minority view — the council disagrees here
- Minervini: watch Trend-template read: 10/12 pass; wait for the soft misses to improve.
- O'Neil: watch CANSLIM read: 2/8 pass; improvement is still needed.
- Weinstein: watch Stage-analysis read: Stage 2 is present; 1 supporting checks need improvement.
76
Strong
Legend Score · rates the stock
Strong (76/100) — held back by eps growth
Our proprietary 0-100 rating — the answer to Wall Street's black-box scores. Five pillars, each computed from real scan data, each explained below in plain English.
- Relative Strength (25%) 100
- Trend Template (25%) 100
- Institutional Footprint (20%) 75
- EPS Growth (15%) 31
- Quality (SMR-like) (15%) 43
RS rank 99: top 1% of all stocks — true leadership. Trend template 8/8: price above rising 50/150/200-day lines — textbook uptrend structure. Institutional score 75: mild accumulation. EPS growth reads +0%, but trailing earnings are negative — that percentage is an artifact, capped. Quality 43: weak fundamentals (sales growth 30, return on equity 39, leverage 100). Updated 2026-10-27.
Earnings
Pre-earnings setup
Next earnings
Thursday, October 29, 2026
Before market open
Exact clock time not supplied by source
Ordinary position sizing suppressed.
Earnings are less than three full trading sessions away; treat the gap as event risk, not ordinary stop-distance risk.
Deterministic evidence
MRNA-0.62%
Sector proxy · XLV+0.00%
Broad market · SPY+0.71%
CatalystPending
Stock reactionNegative
Sector reactionWeak
Opening surgePending
Event riskEarnings-driven
Session internals Mixed
Rule: direction and internals disagree — it met neither the strong nor the weak rule. Judged on internals, not on the size of the move.
Vs prior close-0.62%
From the open+6.30%
Range position78%
GapFaded
QQQ confirmationDiverging (+1.11%)
SMH confirmationDiverging (+2.74%)
Short-term conviction -2 points.
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.
- QQQ, SMH moved against the stock — no index confirmation.
- A sourced earnings report is still pending inside the risk window; ordinary technical conviction is reduced until it is out.
Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.
More stats
52W Low
$22.28
Tight Wks
0
Base
B6
SMA 200
$82.99
RS Line vs High
-18.3%
RS Line Slope
-2.4% ▼
Group Rank
#10/66
ADR%
10.1%
ATR(14)
$23.22 (11.7%)
Vol Pace (live)
N/A
A/D Days
6A / 4D
A/D Rating
B
VDU Bars
0/10 d
Earnings
in 2d
MRNA Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Technical Analysis Report Card
$MRNA · $198.85 · as of 2026-10-26 · multi-factor read
91
/ 100
Reference read from price & volume only — the verdict at the top of the page decides the action.
Trend · Daily / Weekly / Monthly
Daily
▬ Sideways / consolidating
Weekly
▲ Uptrend
Monthly
▲ Uptrend
Moving Averages
50-day$173.86 ↑
100-day$117.33 ↑
200-day$82.99 ↑
Bullish (50 > 200)
RSI (14)
Reading49.8 · Neutral
Neutral — momentum is balanced between buyers and sellers.
MACD (12/26/9)
StateWeakening
Histogram-4.833
Weakening — MACD slipped below its signal line. Histogram contracting.
Bollinger Bands (20,2)
%B / Width34% · 34.5%
Mid-band — no directional band edge in play.
Volume · Buyer vs Seller
Up/Down vol2.89 · Accumulation
Rel volume0.68×
Pocket pivots · 10d0
5d vs 50d vol104%
Heavy vol up / down1 / 1
Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is easing versus its baseline.
- 1 heavy-volume up day vs 1 down in the last 20 sessions.
Support & Resistance
R · $254.4852-week high
Price · $198.85now
S · $182.50swing level
S · $130.38swing level
S · $52.66swing level
Fibonacci · Uptrend swing
23.6%$204.78
38.2%$174.04
50.0%$149.19
61.8%$124.34
78.6%$88.96
Retracement support zones measured from the recent swing low up to the high.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for MRNA — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishVolume accumulationRS 99 (leader)
Want this read in a legend's voice?
Ask a Legend about MRNA
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
How to read the numbers: the setup score (55/100, in the verdict band) rates this trade setup. Each legend's A–D grade rates the same setup against that legend's own checklist — so a high score next to a C grade is not a contradiction. The setup can be strong without fitting that legend's style. When the council disagrees, the verdict band breaks the tie.
Council consensus:
8 of 9 legends are Watching — building, not yet a confirmed buy.
Minervini
Watch
B
Trend-template read: 10/12 pass; wait for the soft misses to improve.
mediumEnter on break of $254.73 pivot with stop at $234.36 (risk 8.0%). SEPA Grade B (5/7).
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $198.85, MA150 $94.85, MA200 $82.99
1.2 150-day MA > 200-day MAMA150 $94.85 vs MA200 $82.99
Failing evidence
2. ROE ≥ 17%ROE -39.2%
2. Revenue growth ≥ 20% YoY-39.9% YoY
O'Neil
Watch
D
CANSLIM read: 2/8 pass; improvement is still needed.
mediumHigh Tight Flag still forming in a top industry group — ideal buy point at $254.73 on big volume. CANSLIM 57.
Passing evidence
C: Quarterly EPS acceleration ≥ 25%+42.1% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 99
Failing evidence
A: Annual earnings & revenue qualityRev -39.9% | ROE -39.2%
N: Near 52-week high or RS line new high21.9% below high | RS line new high: False
Weinstein
Watch
B
Stage-analysis read: Stage 2 is present; 1 supporting checks need improvement.
mediumClassic Stage 2 advancing phase — strong weekly trend confirms uptrend. This is Weinstein's sweet spot: buy and hold while price remains above the 30-week MA.
Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $198.85 vs MA200 $82.99
Failing evidence
Volume expansion above averageVolume ratio 0.68x
dennis
Watch
C
Turtle read: no Donchian signal. The system stays flat until price takes out the 20-day high.
Passing evidence
No breakdown below the 20-day channel20-day low $180.80
Volatility-unit sizing (1N ≈ 1% of equity)1N = $19.23 (9.67% of price); the Turtles size 1 unit so a 1N move ≈ 1% of equity, making the 2N stop ≈ 2% equity risk
Failing evidence
S1: 20-day Donchian breakoutNot confirmed
S2: 55-day Donchian breakoutNot confirmed
zanger
Avoid
C
Zanger read: a hard gate is broken — either the pattern is not one of his six, or the entry is more than 5% past the breakout. He would not touch this.
Passing evidence
Not extended (≤5% above the breakout point)Measured as passing
Partial-profit plan: sell 20-30% at +15-20%Scale 20-30% at $228.68-$238.62; trail the rest
Failing evidence
Named Zanger pattern onlyHigh Tight Flag is not one of Zanger's six
Breakout volume 1.5-2.0x averageData unavailable
zweig
Watch
D
Zweig read: part of his screen passes but not all: Insider buying — wait for the full growth screen before treating this as a Zweig setup.
Passing evidence
EPS growth above the market (≥15% QoQ)+42.1% QoQ — Zweig wants growth above the S&P average
Price strength (RS ≥ 70)RS score 99 — Zweig buys strength, not bargains
Failing evidence
Insider buyingNo insider buying flagged
Monetary conditions: don't fight the FedFed series stored but too thin to read direction
Livermore
Watch
B
Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$198.85
Relative strengthRS 99
Failing evidence
Volume vs average0.68x
Pivotal point cleared on expanding volumeNot confirmed
Darvas
Watch
B
Box-theory read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$198.85
Relative strengthRS 99
Failing evidence
Volume vs average0.68x
Box top broken on heavy volumeNot confirmed
Wyckoff
Watch
B
Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$198.85
Relative strengthRS 99
Failing evidence
Volume vs average0.68x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
Base & Breakout
Breakout follow-through
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▼ Falling
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net +8
Fundamentals & leadership quality — Minervini’s published criteria · 5/7 met
B
5/7 criteria
Separate score from the Minervini Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
+42%
Revenue growth ≥20% YoY
-40%
Gross margin ≥30%
36%
ROE ≥17%
-39%
RS rating ≥80 (leadership)
99
Stage 2 uptrend (Weinstein)
Stage 2
Within 25% of 52W high
-21.9%
Method Playbook
Trade it like Livermore
EXACT LEVELS · PRO
Livermore B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro levelPublished-method rule: Treat the resistance break as a pivotal point only while the primary trend and relative strength remain aligned.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Wait for price and volume to confirm the pivotal-point break; anticipation below the line is not confirmation.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Place the initial stop below the pivotal line or the reaction low that would prove the breakout false.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Raise protection beneath successive higher reaction lows as the trend advances; never move a protective line farther away.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit when price fails the pivotal line, breaks the latest meaningful reaction low, or shows abnormal reversal action.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Pattern Analysis
High Tight Flag
⚠ Volatility widening into breakout
⚠ Late-stage base (#6)
⚠ No base tightness
⚠ Not actionable yet
55
setup score
RS Score
99
Trend template
8/8 ✓
CANSLIM
56.8* (C)
318.9% pole
19.6% pullback
Why This Setup?
D+W Confluence
High Tight Flag · schematic
Pole=319%, pullback=19.6% | Strong trend (8/8) | Top RS (99) | High-confidence pattern (75%) | Accumulation (2.9× up/dn vol) | Stage 2 | Readiness 53/100 (early) | CANSLIM 56.8 (C) | ⚠ Volatility widening into breakout; Late-stage base (#6); No base tightness; Not actionable yet
The Universal Edge Check · context only
What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.
5/7
universals met
- Clear of earnings — not met in 2 days — event risk
- Volume confirms — partly met 0.7× average — light
- A relative-strength leader — met RS rank 99
- Asymmetric reward — met Met — levels are a Pro detail
- In a confirmed uptrend — met Stage 2 · Trend template 8/8
- Not chasing (in range) — met Met — levels are a Pro detail
- Risk is defined — met Met — levels are a Pro detail
Minervini Trend Template
8/8 ✓Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$198.85 vs SMA150 $94.85 / SMA200 $82.99
SMA 150 above SMA 200
SMA150 $94.85 vs SMA200 $82.99
SMA 200 trending up
Slope +17.89 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $173.86
Price above SMA 50
$198.85 vs SMA50 $173.86
30%+ above 52-week low
+792.5% from $22.28
Within 25% of 52-week high
-21.9% from $254.48
RS score above 70
RS 99
Fundamentals
52W Range
76%
Mkt Cap SEC
79.4B
EPS QoQ
+42%
Rev YoY
-40%
ROE
-39%
Gross Margin
36%
D/E
0.07
EPS TTM
$-7.26
Float
399M
Insider
No Buy
Company
Company profile
Moderna, Inc.
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
C
56.8* CANSLIM
* disqualified on C, M
C · Curr. EPS
40
A · Annual EPS
20
N · New Highs
40
S · Supply/Demand
55
L · Leader RS
99
I · Inst. Spons.
100
M · Market
30
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
8/8
W. RS
100
W. Support
$43.68
W. Resist
$254.48
W. Patterns
Record Volume
Weekly Structure
Trend
Neutral
Tight Weeks
0
Confirmation
Neutral
Scan History
20× streakOct 27
High Tight Flag
✓ Gate
55
Oct 26
High Tight Flag
✓ Gate
55
0.0%
Oct 23
Record Volume
✓ Gate
65
-0.6%
Latest News
Headlines for MRNALoading headlines…
Get the full picture on MRNA
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.
Start 7-Day Free Trial